CTT Pharmaceutical Holdings, Inc. filed a Form 4 on October 26, 2026, disclosing a purchase of common shares by the company's CEO and Director, Ryan Khouri, on October 26, 2026.

Key Highlights

  • Reporting person: CTT Pharmaceutical Holdings, Inc., represented by Ryan Khouri, who serves as both CEO and Director.
  • Transaction: 5,880 shares of CTTH acquired (transaction code P) on October 26, 2026.
  • Price paid: $0.057 per share, according to the filing.
  • Resulting ownership: 9,442,536 shares beneficially owned directly following the reported transaction.
  • Earliest transaction date reported: October 22, 2026.
  • No derivative securities: Table II contains no reported derivative transactions.

Ryan Khouri's Open-Market Purchase of CTTH Shares on October 26, 2026

According to the Form 4 filed with the SEC, Ryan Khouri, in his capacity as CEO and Director of CTT Pharmaceutical Holdings, Inc. (ticker: CTTH), acquired 5,880 shares of the company's common stock on October 26, 2026. The filing lists the transaction code as "P," indicating an open-market purchase. The per-share price reported is $0.057. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan, as the applicable checkbox was not checked.

Following the reported transaction, the filing discloses that Khouri directly and beneficially owns 9,442,536 shares of CTTH. The date of earliest transaction noted on the form is October 22, 2026, though the single transaction recorded in Table I is dated October 26, 2026. No derivative securities were reported in Table II of the filing.

The form was signed by Ryan Khouri and dated October 10, 2026. The filing was made by one reporting person. The issuer is identified as CTT Pharmaceutical Holdings, Inc., with the ticker symbol CTTH. No exchange is specified beyond the ticker in the filing's issuer field. The filing contains no explanation of responses in the designated section.

What Was Disclosed

The filing reports a purchase of 5,880 CTTH shares at $0.057 each by CEO and Director Ryan Khouri on October 26, 2026, bringing his directly held beneficial ownership to 9,442,536 shares. No derivative transactions were reported.